Literature DB >> 17079462

Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.

Seok-Hyun Kim1, Hiroshi Nakagawa, Arunasalam Navaraj, Yoshio Naomoto, Andres J P Klein-Szanto, Anil K Rustgi, Wafik S El-Deiry.   

Abstract

To investigate pathways of human esophageal squamous cell transformation, we generated esophageal tumor cells using human telomerase- and SV40-immortalized primary esophageal epithelial cells (EPC2) by overexpression of selected combinations of oncogenes. H-Ras, c-Myc, or Akt, but not epidermal growth factor receptor (EGFR), induced transformed colonies in soft agar. By contrast, bioluminescence imaging of genetically altered immortalized esophageal cells revealed that Akt, EGFR, or H-Ras, but not c-Myc, resulted in tumor formation in immunodeficient mice. H-Ras-driven tumors showed highly tumorigenic phenotypes with 2.6 +/- 0.6 days for doubling, whereas Akt and EGFR tumors doubled every 9.5 +/- 1.6 and 6.1 +/- 1.2 days, respectively. H-Ras-driven tumors expressed the hypoxia-inducible factor target Glut1, whereas Akt- or EGFR-driven tumors had evidence of angiogenesis and no detectable Glut1 expression. Proliferation rates among these tumors were similar, but there was reduced apoptosis in the more aggressive H-Ras-driven tumors that also developed aneuploidy and multiple centrosomes. c-Myc overexpression did not result in tumorigenic conversion but introduction of Bcl-XL into c-Myc-expressing cells generated tumors. Although cytokeratin expression was typical of squamous carcinoma, gene expression profiling was done to compare the four different types of engineered tumors with human esophageal squamous cell carcinomas and adenocarcinomas. Interestingly, c-Myc plus Bcl-XL transformants mimicked squamous carcinomas, whereas H-Ras-, EGFR-, and Akt-driven tumors were similar to adenocarcinomas in their molecular profiles. These genetically engineered models may provide new platforms for understanding human esophagus cancer and may assist in the evaluation of new therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079462     DOI: 10.1158/0008-5472.CAN-06-2104

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

2.  Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer.

Authors:  Yizeng Yang; Hiroshi Nakagawa; Marie-Pier Tetreault; Janelle Billig; Noel Victor; Abha Goyal; Antonia R Sepulveda; Jonathan P Katz
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

3.  p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation.

Authors:  Yizeng Yang; Rohinton S Tarapore; Melissa H Jarmel; Marie-Pier Tetreault; Jonathan P Katz
Journal:  Cell Cycle       Date:  2012-09-18       Impact factor: 4.534

4.  Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.

Authors:  Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
Journal:  Carcinogenesis       Date:  2017-10-26       Impact factor: 4.944

5.  IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment.

Authors:  Mitsuteru Natsuizaka; Hideaki Kinugasa; Shingo Kagawa; Kelly A Whelan; Seiji Naganuma; Harry Subramanian; Sanders Chang; Kei J Nakagawa; Naryan L Rustgi; Yoshiaki Kita; Shoji Natsugoe; Devraj Basu; Phyllis A Gimotty; Andres J Klein-Szanto; J Alan Diehl; Hiroshi Nakagawa
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

6.  Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.

Authors:  Mitsuteru Natsuizaka; Shinya Ohashi; Gabrielle S Wong; Azal Ahmadi; Ross A Kalman; Daniela Budo; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Hiroshi Nakagawa
Journal:  Carcinogenesis       Date:  2010-05-31       Impact factor: 4.944

7.  IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms.

Authors:  Munenori Takaoka; Seok-Hyun Kim; Takaomi Okawa; Carmen Z Michaylira; Douglas B Stairs; Cameron N Johnstone; Claudia D Andl; Ben Rhoades; James J Lee; Andres J P Klein-Szanto; Wafik S El-Deiry; Hiroshi Nakagawa
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

8.  Assessment of acridine orange and SYTO 16 for in vivo imaging of the peritoneal tissues in mice.

Authors:  J A Udovich; D G Besselsen; A F Gmitro
Journal:  J Microsc       Date:  2009-05       Impact factor: 1.758

9.  High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.

Authors:  Shujuan J Xia; Dara D Holder; Bruce R Pawel; Chune Zhang; Frederic G Barr
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

10.  H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression.

Authors:  Valeska Portela Lima; Marcos Antonio Pereira de Lima; Angela Rosa André; Márcia Valéria Pitombeira Ferreira; Marcos Aurélio Pessoa Barros; Sílvia Helena Barem Rabenhorst
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.